Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2543652rdf:typepubmed:Citationlld:pubmed
pubmed-article:2543652lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:2543652lifeskim:mentionsumls-concept:C0303403lld:lifeskim
pubmed-article:2543652pubmed:issue4lld:pubmed
pubmed-article:2543652pubmed:dateCreated1989-7-20lld:pubmed
pubmed-article:2543652pubmed:abstractTextMonoclonal antibodies 10B, 8C and M2A were conjugated with cyclic DTPA anhydride to a substitution level of 1-2 mol DTPA/mol antibody. The DTPA-conjugated antibodies were purified by size-exclusion mini-column chromatography and labelled with [111In]In acetate to a specific activity of 37-74 kBq/micrograms (1-2 microCi/micrograms). The radiochemical purity of the antibody preparation was 76-81%. The immunoreactive fraction of the radiolabelled antibodies ranged from 0.17 to 0.31, significantly lower than that of their radioiodinated analogs.lld:pubmed
pubmed-article:2543652pubmed:languageenglld:pubmed
pubmed-article:2543652pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2543652pubmed:citationSubsetIMlld:pubmed
pubmed-article:2543652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2543652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2543652pubmed:statusMEDLINElld:pubmed
pubmed-article:2543652pubmed:issn0883-2889lld:pubmed
pubmed-article:2543652pubmed:authorpubmed-author:HouldRRlld:pubmed
pubmed-article:2543652pubmed:authorpubmed-author:MarksAAlld:pubmed
pubmed-article:2543652pubmed:authorpubmed-author:ReillyRRlld:pubmed
pubmed-article:2543652pubmed:authorpubmed-author:SheldonKKlld:pubmed
pubmed-article:2543652pubmed:issnTypePrintlld:pubmed
pubmed-article:2543652pubmed:volume40lld:pubmed
pubmed-article:2543652pubmed:ownerNLMlld:pubmed
pubmed-article:2543652pubmed:authorsCompleteYlld:pubmed
pubmed-article:2543652pubmed:pagination279-83lld:pubmed
pubmed-article:2543652pubmed:dateRevised2009-6-4lld:pubmed
pubmed-article:2543652pubmed:meshHeadingpubmed-meshheading:2543652-...lld:pubmed
pubmed-article:2543652pubmed:meshHeadingpubmed-meshheading:2543652-...lld:pubmed
pubmed-article:2543652pubmed:meshHeadingpubmed-meshheading:2543652-...lld:pubmed
pubmed-article:2543652pubmed:meshHeadingpubmed-meshheading:2543652-...lld:pubmed
pubmed-article:2543652pubmed:meshHeadingpubmed-meshheading:2543652-...lld:pubmed
pubmed-article:2543652pubmed:meshHeadingpubmed-meshheading:2543652-...lld:pubmed
pubmed-article:2543652pubmed:meshHeadingpubmed-meshheading:2543652-...lld:pubmed
pubmed-article:2543652pubmed:year1989lld:pubmed
pubmed-article:2543652pubmed:articleTitleLabelling of monoclonal antibodies 10B, 8C, and M2A with indium-111.lld:pubmed
pubmed-article:2543652pubmed:affiliationToronto General Hospital, Division of Nuclear Medicine, Ontario, Canada.lld:pubmed
pubmed-article:2543652pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2543652pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed